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Abstract
Background: Bone morphogenetic proteins (BMPs) are members of the TGF-beta superfamily
and were originally identified as proteins that induce ectopic bone formation. BMPs were shown
subsequently to be involved in several biological processes during development and in adult tissues
through the regulation of the growth, differentiation and apoptosis of various cell types. An alkaline
phosphatase (ALP)-based assay is the most widely used assay to evaluate BMP activity. However,
the ALP assay is not rapid and not sensitive enough to measure BMP activity at physiological
concentrations. In this paper, we describe a highly sensitive, rapid, and specific cell-based assay for
the quantification of BMP activity.
Results: Two cells lines, C2C12 and HepG2 were stably transfected with a reporter plasmid
consisting of BMP-responsive elements from the Id1 promoter fused to a luciferase reporter gene.
Exposure of cells containing this construct to BMPs induces the expression of luciferase, which can
be quantified with a luminometer. The bioassay is specific for BMPs and can detect BMP-4 activity
at a concentration as low as 3 pM. Related family members, such as TGF-beta1, TGF-beta2 and
TGF-beta3, do not induce the reporter gene.
Conclusion: The assay is rapid (less than 24 hours) and can be used, as described in this paper, to
measure BMP activity in complex solutions and in cell culture in a simple and efficient way.
Background
Bone morphogenic proteins (BMPs) are members of the
transforming growth factor beta (TGF-β) superfamily that
consists of a number of structurally related polypeptides
that control a broad array of cellular processes, including
cell proliferation, apoptosis and differentiation [1,2].
Although BMPs originally were identified as proteins that
induced formation of bone when implanted into the mus-
cle of adult rats [3,4], BMPs also play crucial roles in dor-
soventral patterning of the mesoderm, neural patterning,
skeletal development, and limb formation [5]. Altered
BMP signaling pathways are associated with several
human diseases including arthritis, osteoporosis, kidney
diseases, cancer and pulmonary hypertension [6-10].
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BMPs are synthesized as precursor proteins. After dimeri-
zation, the precursor molecules are proteolytically cleaved
within the cell by proprotein convertases at the multibasic
motif RXXR to yield the active, carboxy-terminal mature
protein dimer [11-13]. BMPs exert their biological activity
through combinations of type I and type II serine/threo-
nine kinase receptors. Three distinct BMP type I receptors,
i.e. activin receptor-like kinase (ALK)-2, ALK3 (also
termed BMPRIA) and ALK6 (BMPRIB) and three distinct
type II receptors, i.e. BMP type II receptor (BMPRII) and
two activin type II receptors (ActR-IIA and ActR-IIB) have
been identified [1]. Upon ligand binding, the type II
receptors phosphorylate the type I receptor, which in turn
initiates the downstream signaling process through phos-
phorylation of BMP-specific receptor-regulated Smads (R-
Smads), i.e. Smad1, Smad5 or Smad8 [14-16]. R-Smads
form a complex with Smad4 and translocate into the
nucleus where the complex regulates the transcription of
various target genes through its association with other
transcription factors [17]. In contrast, TGF-β and activin
signaling pathways recruit Smad2 and Smad3, which can
also form heteromeric complexes with Smad4.
In addition to the tissue-specific expression of BMPs and
their surface receptors, the biological activity of BMPs is
regulated by a number of extracellular inhibitory mole-
cules, such as chordin, noggin and follistatin [18]. More-
over, BMP signaling can be modulated by cross-talk with
other pathways. TGF-β and BMP can modulate the activity
of each other through competition for the interaction of
their respective R-Smad with Smad4 or through activation
of inhibitor Smads (I-Smads) [19,20].
The biological effects of BMPs have been used to develop
quantitative bioassays. To date, alkaline phosphatase
activity, a marker of osteoblast differentiation, measured
in mesenchymal cells upon BMP stimulation, is the in-
vitro assay most widely used among the research commu-
nity to evaluate BMP activity [21]. However, the response
in this assay is slow, usually taking between two to five
days, and the assay is not sensitive enough to measure the
low BMP concentrations generated in many biological
systems.
Here we describe the development of a rapid and highly
sensitive cell-based assay to measure BMP activities in dif-
ferent biological contexts. C2C12 mouse mesenchymal
cells and HepG2 human hepatoma cells were stably trans-
fected with a construct consisting of a BMP/Smad-
dependent specific enhancer derived from the Id1 pro-
moter and fused to a luciferase reporter gene [22].
Through screening and cloning, we generated two stable
cell lines, C2C12BRA and HepG2BRA, which can measure
BMP activity with high sensitivity and in various biologi-
cal situations.
Results
Expression of BMP and BMPRs in the HepG2BRA and 
C2C12BRA
C2C12 mouse myoblast and HepG2 human hepatoma
cell lines, which are known to respond to BMPs, were sta-
bly transfected with the BRE-Luc construct. This construct
contains regions of the mouse Id1 promoter, which are
important for the induction of Id1 transcription by BMPs,
fused to a luciferase reporter gene. After cloning the trans-
fected C2C12 and HepG2 colonies, cells from C2C12
clone 9 (named C2C12BRA) and HepG2 clone 15
(named HepG2BRA) were found to be the most sensitive
upon stimulation with recombinant BMP-4 (data not
shown). These clones were used for all subsequent exper-
iments.
To obtain a comprehensive picture of the repertoire of
BMPs and BMPRs expressed by C2C12BRA and
HepG2BRA cells, we analyzed the expression of mRNAs
coding for BMPs and BMPRs. Total RNA was isolated from
C2C12BRA and HepG2BRA cells and subjected to RT-
PCR. HepG2BRA cells expressed the mRNA for BMP-4
(Fig. 1A). No PCR products were observed for BMP-2,
BMP-6 and BMP-7. We next analyzed the expression of
mRNA coding for the three type I receptors (ALK2, ALK3
and ALK6) and the three type II receptors (ActR-IIA, ActR-
IIB and BMPRII). C2C12BRA cells express ALK2, BMPRII
and ActR-IIA mRNA (Fig. 1B). Trace levels of ALK3 and
ActR-IIB were detected, whereas no expression of ALK6
was observed. HepG2BRA cells express ALK2, BMPRII and
ActR-IIB mRNA. Trace levels of ALK3 were detected,
whereas no PCR products were obtained for ALK6 and
ActR-IIA (Fig. 1B).
Dose-dependent induction of the BRE-Luc contruct by 
BMPs
HepG2BRA and C2C12BRA cells were assayed for the
induction of luciferase expression using a broad range of
BMP-2, BMP-4, BMP-6 and BMP-7 concentrations (Fig.
2). HepG2BRA and C2C12BRA cells demonstrated equiv-
alent dose-responses when stimulated with BMP-2 (ED50
~ 0.25–0.35 nM; sensitivity 40–80 pM) (Fig. 2A) and
BMP-6 (ED50 ~ 0.2–0.4 nM; sensitivity 40–150 pM), but a
different dose-response curve for BMP-4 and BMP-7 (Fig.
2B, 2C and 2D, respectively). BMP-4 was the most potent
inducer of luciferase activity with an ED50 of approxi-
mately 10 pM and 50 pM for C2C12BRA and HepG2BRA
cells, respectively. BMP-7 was the least potent inducer of
luciferase expression with an ED50 of approximately 0.5
nM and a sensitivity between 0.1 to 0.15 nM for the
HepG2BRA reporter assay. The dependence of the assay
for the ligand was shown for BMP-4 by inclusion of a neu-
tralizing antibody for BMP-4 (MAB 757) that blocked the
luciferase response (data not shown).BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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Effect of incubation time on luciferase activity
Next we tested the response of C2C12BRA cells to recom-
binant BMP-4 using different incubation times and differ-
ent concentrations of the growth factor. At a
concentration of recombinant BMP-4 as low as 3.5 pM,
the sensitivity of the C2C12BRA cells was equivalent for
incubation times of 5 h, 10 h and 15 h but decreased at an
incubation time of 24 h (Fig. 3). When C2C12BRA cells
were stimulated with concentrations above 3.5 pM, incu-
bation times between 10 h and 15 h were optimal. Shorter
or longer incubation times yielded decreased responses
(Fig. 3). It is interesting that the luciferase response
declined at the longer time points. The reasons for this are
unclear but may relate to the kinetics of gene expression
and stability of the luciferase.
Specificity of the assay
Next we investigated the effect of different concentrations
of serum on the stimulation of luciferase activity with
recombinant BMP-4. The responses of HepG2BRA and
C2C12BRA cells differed with respect to serum concentra-
tions. The presence of serum impaired the response of
HepG2BRA cells at all concentrations of rBMP-4 tested,
with a strong decrease in sensitivity with medium contain-
ing 10% FBS and a mild decrease with serum concentra-
tions of 1%, 2% and 5% (Fig. 4A). With HepG2BRA cells,
the luciferase response was best using serum-free medium
and BSA added at a final concentration of 0.1% (DMEM-
BSA). On the other hand, 10% serum had only a minor
effect on the response of C2C12BRA cells compared to
incubation with DMEM-BSA medium (Fig. 4B). At a low
BMP-4 concentration (7 pM), the relative luciferase activ-
ity in the presence of 10% FBS was actually higher com-
pared to that with serum-free medium. Addition of 1% or
2% serum shifted the curve downward at all BMP-4 con-
centrations tested (Fig. 4B).
We also tested the induction of luciferase activity with
other members of the TGF-β superfamily, such as TGF-β1,
TGF-β2, TGF-β3, as well as TGF-β-unrelated growth fac-
tors, such as FGF-2 and VEGF. As shown in Fig. 5,
although BMP-4 at 14 pM induced a strong luciferase
expression, there was no elevation of luciferase activity
when cells were incubated with different isoforms of TGF-
β even at concentration as high as 1 ng/ml. 10 ng/ml of
bFGF or VEGF did not induce luciferase expression.
It is well established that TGF-β and BMP can modulate
the activity of each other through cross-talk of their
respective pathways [20]. Therefore, we examined
whether TGF-β1 would affect the induction of luciferase
activity by recombinant BMP-4. As shown in Fig. 6A,
increasing the concentration of active TGF-β1 reduces the
luciferase activity induced by BMP-4 with both
C2C12BRA and HepG2BRA cells. Similar results were
obtained with TGF-β2 and TGF-β3 (Data not shown). We
performed the opposite experiment using TGF-β-respon-
sive reporter cells (TMLC) that produce luciferase activity
in response to TGF-β [23]. TMLC were co-stimulated with
250 pg/ml of TGF-β1 and increasing concentrations of
BMP-4 (Fig. 6B). Compared to the effect of TGF-β on the
BMP-responsive reporter cells, BMP-4 had a very slight
effect on luciferase activity induced by TGF-β1 in TMLC
cells even at a concentration as high as 2.5 ng/ml.
Measurement of BMP activity from biological samples
We tested the BMP assay with conditioned medium from
COS cells transiently transfected with either a dorsalin-1
(Ds1-1) or a BMP-4 expression plasmid. Dorsalin is mem-
ber of the BMP family that regulates dorsoventral pattern-
ing of the neural tube. Like BMPs, Dsl-1 induces alkaline
phosphatase synthesis in an osteoblast differentiation
assay [24]. We found that both Dsl-1- and BMP-4-condi-
tioned medium induced the expression of luciferase,
whereas mock conditioned medium had no effect (Fig.
7A). Conditioned medium from 293T cells transfected
Expression of BMP and BMPRs in HepG2BRA and  C2C12BRA cells Figure 1
Expression of BMP and BMPRs in HepG2BRA and 
C2C12BRA cells. Total RNA from C2C12BRA and 
HepG2BRA cells was isolated and used as a template for the 
reverse transcriptase-polymerase chain reaction (RT-PCR) 
to examine the expression of BMP and BMPRs. G3PDH gene 
expression was used as an internal control. PCR products 
were separated in 1% agarose gel and visualized after ethid-
ium bromide staining. (A) Representative RT-PCR analysis of 
total RNA using specific primers for BMP-2, BMP-4, BMP-6 
and BMP-7. (B) Representative RT-PCR analysis of total RNA 
using specific primers for BMP type I receptors (ALK2, 
ALK3, ALK6) and BMP type II receptors (BMPR-II, ActR-IIA, 
ActR-IIB). Similar results were obtained in two separate 
experiments.BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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with a BMP-7 expression plasmid led to a substantial
increase in luciferase activity compared to mock condi-
tioned medium (Fig. 7B). We also cocultured C2C12BRA
cells with 293 cells stably transfected with BMP-7 expres-
sion plasmid and observed a substantial induction of luci-
ferase activity compared to 293 cells stably transfected
with an empty plasmid (Fig. 7C).
Dose-dependent induction of the BRE-Luc construct by BMPs Figure 2
Dose-dependent induction of the BRE-Luc construct by BMPs. C2C12BRA and HepG2BRA cells were added to 96-
well plates at 4 × 103 cells per/well and 5 × 103 cells/well, respectively. The reporter cells were incubated with increasing con-
centrations of the indicated recombinant BMPs in DMEM, 0.1% BSA. After 15 h incubation, BMP activity was assessed by meas-
uring luciferase activity in the cell lysates. (A) BMP-2. (B) BMP-4. (C) BMP-6. (D) BMP-7. Background luciferase level in the 
control sample (no BMP) was subtracted from each of the experimental values. The results are expressed as relative luciferase 
units (RLU). Each point represents the mean ± SEM of triplicate wells from 1 representative experiment. Similar results were 
obtained in two separate experiments.BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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We determined if the reporter assay could be used to
detect and quantify BMP activity in biological samples
without any enrichment, i.e. concentrating the condi-
tioned medium or overexpressing BMP in cells. For this
purpose we measured BMP activity in conditioned
medium from lung fibroblasts established from wt and
Ltbp-4 hypomorphic mice (wt and Ltbp-4-/- cells, respec-
tively). It was reported that Ltbp-4-/-  lung fibroblasts
express more BMP-4 and less gremlin, a BMP inhibitor,
compared to the wt cells [25]. As shown in Fig. 7D, condi-
tioned medium from Ltbp-4-/-  cells induced luciferase
activity more efficiently than wt cells in C2C12BRA cells.
The difference between wt and Ltbp-4-/- cells corresponded
to a BMP-4 concentration of ~3.5 pM. We also cocultured
C2C12BRA cells with wt and Ltbp-4-/- lung fibroblasts and
again observed more BMP activity in Ltbp-4-/- cells com-
pared to wt cells (Fig. 7D). In fact, the coculture assay
yielded almost twice the activity as the assay using condi-
tioned medium. Inclusion in the assay of noggin, an
inhibitor of BMP, blocked the BMP activity observed in
Ltbp-4-/- cells (Fig. 7E).
Discussion
Currently, the ALP assay is the most widely and routinely
used cell-based assay to measure BMP activity. ALP expres-
sion is a marker of osteoblast differentiation and BMP-
induced osteogenic differentiation of mesenchymal cells.
However, this assay has several drawbacks. The time
required to perform the assay is long, usually between two
to five days. This assay is not sensitive enough to detect
BMP concentrations generated in many biological systems
and ALP expression can be affected negatively or posi-
tively by a variety of other signaling pathways, such as
Sonic hedgehog, FGF-2 or Wnt/beta-catenin [26-28].
In the present paper, we describe the establishment of a
highly sensitive and specific assay to measure BMP activ-
ity. Two stable cell clones, C2C12BRA and HepG2BRA,
were isolated after transfection of C2C12 and HepG2 cells
Effect of serum on the assay Figure 4
Effect of serum on the assay. HepG2BRA (A) and 
C2C12BRA (B) cells were incubated with DMEM containing 
the indicated concentration of rBMP-4 with 0.1% BSA or 1%, 
2%, 5% and 10% FBS. Luciferase activity was measured after 
15 h of incubation. Background luciferase level in the control 
sample (no BMP) was subtracted from each of the experi-
mental values. The results are expressed as relative luciferase 
units (RLU). Each point represents the mean ± SEM of tripli-
cate wells from one representative experiment. Similar 
results were obtained in two separate experiments.
Effect of incubation time on BMP assay sensitivity Figure 3
Effect of incubation time on BMP assay sensitivity. 
C2C12BRA cells were plated at 4 × 103 cells/well. Recom-
binant BMP-4 at the indicated concentrations was incubated 
with the cells for 5, 10, 15 or 24 h prior to assaying for luci-
ferase activity. Background luciferase level in the control 
sample (no BMP) was subtracted from each of the experi-
mental values. The results are expressed as relative luciferase 
units (RLU) (the activity with 14 pM of BMP-4 after 10 h 
incubation time equals one). Each point represents the mean 
± SEM of triplicate wells from one representative experi-
ment. Similar results were obtained in two separate experi-
ments.BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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with an expression construct containing distinct sequence
motifs derived from the mouse Id1 promoter fused to a
luciferase gene. When compared to other available cell-
based bioassays or protein-based assays, our assay pro-
vides improved sensitivity for several BMP types, is faster,
and is more specific for the measurement of BMP activity
in complex biological solutions and in various biological
situations.
Recently, another cell-based assay was described using
C3H10T1/2 embryonic mouse cells stably transfected
with the same reporter construct that we used in our assay
[29]. Although the C3H10T1/2 assay can detect recom-
binant BMP-2 in DMEM-BSA at twofold lower concentra-
tion than our assay, our assay is more sensitive when
measuring the activity of BMP-4 (3 pM compared to a
concentration >250 pM) and BMP-7 (125 pM compared
to a concentration >300 pM). Moreover, the sensitivity of
the C3H10T1/2 assay was diminished when performed in
the presence of large excess of foreign protein, i.e. concen-
trations of serum above 2%. Although the sensitivity of
HepG2BRA cells was also decreased by increasing concen-
tration of serum, the ability of C2C12BRA cells to measure
concentrations of recombinant BMP-4 as low as 7 pM was
not affected by concentrations of serum as high as 10%.
Thus, depending upon the biological medium to be
assayed, one could use either C2C12BRA or HepG2BRA
cells. Finally, we show how the assay sensitivity can be
enhanced by cocultures of test cells and reporter cells.
Radioimmunoassays and enzyme linked immunoabsorb-
ent assays (ELISA) are sensitive and specific and have been
developed for BMPs [30,31]. The disadvantages of these
assay are that they are expensive and that they measure
both biologically active and inactive BMPs. Recently, a
new protein based assay named ELIRA (enzyme-linked
Effect of TGF-β1 on BMP-4 signaling pathway Figure 6
Effect of TGF-β1 on BMP-4 signaling pathway. (A) 
C2C12BRA and HepG2BRA cells were treated with 14 pM 
of rBMP-4 in combination with increasing concentrations of 
TGF-β1. After 15 h, BMP activity was assessed by measuring 
luciferase activity in the cell lysates. Background luciferase 
level in the control sample (no BMP) was subtracted from 
each of the experimental values. The results are expressed as 
relative luciferase units (RLU) (the activity with 14 pM BMP-4 
alone equal to one). (B) TGF-β-responsive reporter cells 
(TMLC) were stimulated with 250 pg/ml of TGF-β1 and 
increasing concentrations of BMP-4. After 16 h, TGF-β1 
activity was assessed by measuring luciferase activity in the 
cell lysates. Each point represents the mean ± SEM of tripli-
cate wells from one representative experiment. Similar 
results were obtained in two separate experiments.
Effects of growth factors on the reporter-cell assay Figure 5
Effects of growth factors on the reporter-cell assay. 
C2C12BRA cells were stimulated with 1ng/ml (TGF-β1, 
TGF-β2 and TGF-β3) or 10 ng/ml (FGF-2 and VEGF) of 
growth factors and the luciferase activity measured after 15 
h. Treatment with 14 pM of rBMP-4 served as a positive con-
trol. Background luciferase level in the control sample (no 
BMP) was subtracted from each of the experimental values. 
The results are expressed as relative luciferase units (RLU). 
Each point represents the mean ± SEM of triplicate wells 
from one representative experiment. Similar results were 
obtained in two separate experiments.BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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immunoreceptor assays) was developed for quantifica-
tion of recombinant BMP-2 [32]. Although this assay
measures the quantity of BMP-2 that binds to its recep-
tors, this binding does not necessarily mean that the pro-
tein is biologically active. Our assay quantifies only BMP
that is biologically active as opposed to immuno-reactive
BMP. Moreover, the lower detection limit of the ELIRA
was high (~11 nM) compared to our assay and assay per-
formance was disturbed by the presence of foreign pro-
teins [32].
The differential sensitivity of C2C12BRA and HepG2BRA
cells observed for different BMPs might be explained by
the different expression patterns of endogenous BMPs and
BMP receptors as characterized by RT-PCR (Fig. 1). Dis-
tinct BMPs have different effects depending on the nature,
the absolute number and the different combinations of
BMP type I and type II receptors on the cell surface [1]. The
higher sensitivity of C2C12BRA cells compared to
HepG2BRA cells when measuring BMP-4 activity might be
due to the lower endogenous expression of BMP-4 in
C2C12BRA cells compared to HepG2BRA cells (Fig. 1A).
Although our assay is not BMP-isoform specific, the
appropriate addition of neutralizing antibodies for a
given BMP and the use of a standard curve should allow
the quantification of specific biologically active BMPs.
As shown in Fig. 6A, whereas our assay is specific for BMP,
luciferase expression induced by BMP can be affected by
active TGF-β. To our knowledge, this is the first time that
this observation has been made for this BMP reporter con-
struct. Although TGF-β does not have an effect on Id
expression by itself, TGF-β might indirectly modify the
effect of BMP by sequestering Smad4 or induction of the
expression of I-Smads [19,20,22]. TGF-β activity meas-
ured with a TGF-β reporter assay was not affected by
recombinant BMP-4 (Fig. 6B). This is likely due to the lack
of functional BMP-Smad pathway in these cells. Interest-
ingly, the sensitivity of C2C12BRA for BMP-4 is only min-
imally affected by high concentrations of serum known to
contain TGF-β (Fig. 4B). This observation can be
explained by the fact that TGF-β in serum is in a latent
form that must be activated in order to bind to its receptor
and thus interfere with the BMP signaling pathway [33].
Beside its high sensitivity and specificity, another major
advantage of our assay is the possibility to measure BMP
activity from biological samples in a simple and efficient
way. Quantification of BMP activity in complex biological
solutions, as opposed to a defined medium, such as
DMEM-BSA, is necessary for a cell-based assay to be useful
to address specific problems related to BMP activity. In
this paper, we describe the use of this assay in several ways
to enhance its utility. First, we tested the possibility of this
assay to measure BMP activity in non-defined medium.
Our BMP reporter assay detected BMP activity in the con-
ditioned medium of COS and 293T cells transfected with
BMP-4 and BMP-7 expression plasmids, respectively (Fig.
BMP activity measured in biological samples Figure 7
BMP activity measured in biological samples. (A) 4 × 
103 C2C12BRA cells/well were treated with supernatants of 
COS cells transfected with either a BMP-4 or a Dsl expres-
sion vector. Empty pcDNA3 plasmid was used as a mock 
control (B) 4 × 103 C2C12BRA cells/well were treated with 
supernatants of 293T cells transfected with the empty plas-
mid pcDNA3 (mock) or BMP-7 expression vector. (C) 4 × 
103 C2C12BRA cells/well were cocultured with 4 × 103 293 
cells/well stably transfected with a pcDNA3 (mock) or a 
BMP-7 expression plasmid. After 24 h, luciferase activity was 
measured. (D) 4 × 103 C2C12BRA cells/well were cocul-
tured with 1 × 104 wt or Ltbp-4 hypomorphic (Ltbp-4-/-) lung 
fibroblasts. Luciferase activity was measured after 24 h. Con-
ditioned medium from the coculture was collected from wt 
and Ltbp-4-/- lung fibroblasts and applied to C2C12BRA cells 
for 15 h to measure the amount of BMP activity. (E) 5 × 103 
wt or Ltbp-4 hypomorphic (Ltbp-4-/-) lung fibroblasts were 
added to a 96 well plate. After 24 h, 4 × 103 C2C12BRA cells 
were added with or without 2 μg/ml of recombinant noggin. 
Luciferase activity was measured after 24 h. The results are 
expressed as relative luciferase units (RLU). Each point rep-
resents the mean ± SEM of triplicate wells from one repre-
sentative experiment. Similar results were obtained in two 
separate experiments.BMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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7A and 7B respectively). Interestingly, the amount of BMP
activity detected in the conditioned medium was highly
dependent on the cell line used to overexpress the specific
BMP isoform. This might be due, as mentioned in previ-
ous studies, to the cell-specific expression pattern of pro-
protein convertases involved in the processing of the BMP
inactive precursor form [34]. Second, C2C12BRA cells
measure BMP activity when cocultured with 293 cells sta-
bly transfected with a BMP-7 expression vector (Fig. 7C).
The advantage of this arrangement is that one can meas-
ure very low concentrations of BMP because of an increase
in the local concentration of the cytokine without much
dilution in the media. Third, this assay can measure
endogenous BMP secreted by cells. Disruption of the Ltbp-
4 gene in mice results in abnormal lung development due
to an enhanced activation of the BMP-4 signaling pathway
both in vitro and in vivo [25]. Microarray analysis
revealed that isolated Ltbp-4-/- lung fibroblasts from these
mice express more BMP-4 and less of its inhibitor gremlin
compared to wt cells [25]. Here we confirm these findings
by showing that Ltbp-4-/- cells produce more BMP activity
than wt cells (Fig. 7D). Interestingly, coculture of the BMP
reporter assay cells with Ltbp-4-/- cells detected more BMP
activity than when reporter cells were incubated with con-
ditioned medium. This is probably due to an increase in
the local concentration of BMP-4 without dilution of the
cytokine in the media. The difference in luciferase activity
between wt and Ltbp-4-/- cells was BMP-specific as the
inclusion of noggin, a specific BMP inhibitor, in the coc-
ulture blocked the luciferase response induced by Ltbp-4-/
- cells (Fig. 7E).
Conclusion
We have generated a rapid, specific and sensitive cell-
based bioassay that can be used to measure BMP activity
in complex solutions and in various biological contexts.
Moreover, this bioassay can be used to study BMP signal-
ing and to screen and identify new targets to modify BMP
signaling pathways either positively or negatively.
Methods
Cell lines and reagents
C2C12, HepG2 (obtained from Dr. A. Kumar; New York
University, NY), COS, 293, and 293T cells were grown in
Dulbecco's Modified Eagle's Medium (DMEM) and sup-
plemented with 10% fetal calf serum and antibiotics.
Mink lung epithelial cells (TMLC) stably transfected with
a plasmid containing the luciferase cDNA downstream of
a TGF-β-sensitive portion of the plasminogen activator
inhibitor 1 promoter were used as described [23]. Lung
fibroblast cultures from adult wt and Ltbp-4-/- mice were
obtained from Dr. K. Koli (University of Helsinki, Hel-
sinki, Finland) and used as described [25]. 293 cells stably
transfected with a BMP-7 expression vector have been pre-
viously described [35].
Recombinant human BMP-2, -4, -6, -7 and mouse noggin
were purchased from R&D Systems Inc. Recombinant
FGF-2 and VEGF were a gift from Dr. P. Mignatti (New
York University School of Medicine, New York, NY
10016, USA).
pcDNA3 vector was obtained from Invitrogen (Carlsbad,
CA, USA). The pMT21 expression vector containing Myc-
tagged chick Dorsalin [24] was a gift from Dr. T. Jessell
(Columbia University, NY). BMP-4 expression vector was
a gift from Dr. A.H. Brivanlou (The Rockefeller University,
NY). pNeo-(BRE)2-Luc was generated by inserting a neo-
mycin resistance gene into pGL3 (BRE)2-Luc vector [22].
RNA extraction, reverse transcription and polymerase 
chain reaction (PCR)
Total RNA was isolated from cells with Trizol (Invitro-
gen). cDNA was generated from RNA with reverse tran-
scriptase and used as a template for amplification with
Taq polymerase. Each PCR reaction consisted of initial
denaturation at 94°C for 30s. The cycling parameters were
as follows: 94°C for 30 s, 59°C for 45 s and 72°C for 1
min. After 25 cycles, reaction underwent a final extension
at 72°C for 5 min. Amplification products were electro-
phoresed on 1% agarose gels and visualized by ethidium
bromide staining The primer sequences used for PCR
amplification, based on published sequences, were as fol-
lows: 5'-TTTGGACCTGGCTAATGGAG-3' and 5'-GGCCACT-
TATTGTTGGCACT-3' for human ActR-IIa; 5'-
CTCCCTCACGGATTACCTCA-3'  and 5'-AGGGCAGCATG-
TACTCATCC-3' for Human ActR-IIb; 5'-AATTGGCT-
TCTCGTTGCACT-3' and 5'-CATCTCCCAGATCCATGCTT-3'
for mouse ActR-IIa; 5'-CATCATCACGTGGAACGAAC-3' and
5'-CTTGTGGACAACCACCTCCT-3' for mouse Act-RIIb; 5'-
CCTTGGATGAGCGTCCAGTTG-3' and 5'-
AGCCGAGCCTCTGCATC-3' for BMPR-II; 5'-AGACACTC-
CAGTACCCAGCTG-3' and 5'-GCTGTGAGTCTTGCG-
GATGG-3' for ALK-2; 5'-TGGTTCAGCGAACTATTGCCA-3'
and 5'-TCAGCCATGATGTAGGGCTGG-3' for ALK-3; 5'-
AGTGGATCAGGCCTCCCTCGC-3' and 5'-CACTTCTGGAG-
GCATATAGCG-3' for ALK-6; 5'-ACTTCCAGAGATGAGT-
GGGA-3' and 5'-ATCTTGGTGCAAAGACCTGCT-3' for
mouse BMP-2; 5'-ACTACCAGAAACGAGTGGGA-3' and 5'-
ATCTTGGTGCAAAGACCTGCT-3' for human BMP-2; 5'-
CAGATGTTTGGGCTGCGCC-3' and 5'-AGGTGAGTCACCT-
CAATGGC-3' for BMP-4; 5'-TTCCTCAACGACGCGGACAT-
3' and 5'-CCACCATGAAGGGCTGCTT-3' for BMP-6; 5'-
TGGACCTGTACAACGCCATG-3'  and 5'-TGGTTGCTGGT-
GGCTGTGAT-3' for BMP-7. 5'-ACCACAGTCCATGCCAT-
CAC-3' and 5'-TCCACCACCCTGTTGCTGTA-3' for G3PDH.
TGF-β bioassay
To measure TGF-β activity, TMLC cells in 96 wells were
incubated with recombinant protein diluted in serum-free
DMEM-0.1% BSA. Sixteen hours later, TGF-β was assessedBMC Cell Biology 2007, 8:41 http://www.biomedcentral.com/1471-2121/8/41
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by measuring luciferase activity in cell lysates as described
previously [23]. All experiments were done in triplicate
and repeated at least two times with similar results.
Cell transfection
COS and 293T cells were transiently transfected in 6-well
dishes with 1 μg of DNA per well using Lipofectamine
Plus. After 16 h, the medium was changed to serum-free
OptiMEM (GIBCO BRL) and conditioned for 24 h. Con-
ditioned medium was precleared by centrifugation and
tested in the BMP reporter assay.
To generate BMP reporter cells, C2C12 and HepG2 cells
were stably transfected with pNeo-(BRE)2-Luc. Briefly,
HepG2 and C2C12 cells were seeded at 8 × 104 cells/well
in 35 mm dish for 24 h at which point they were trans-
fected with 1 μg of pNeo-(BRE)2-Luc DNA using Lipo-
fectamine. Twenty-four hours later, cells were reseeded at
different densities and selected for antibiotic resistance
using 700 μg/ml geneticin. The resistant colonies were iso-
lated, expanded, and tested in reporter cell assays. Clone
9 for C2C12 (named C2C12BRA) and clone 15 for
HepG2 (named HepG2BRA) were found to be the most
sensitive upon stimulation with recombinant BMP-4.
BMP bioassay and BMP co-culture bioassay
Unless indicated, the BMP assay was performed as fol-
lows: C2C12BRA and HepG2BRA cells were added to 96-
well plates culture dishes at 4 × 103 cells/well and 5 × 103
cells/well, respectively. The cells were allowed to attach
overnight. The medium was replaced with the indicated
medium containing the recombinant protein to be tested
for BMP activity. After 14 h, cells were washed twice with
PBS and cell extracts were prepared with 45 μl of 1× cell
lysis buffer (BD Pharmingen). 35 μl of the lysate was
transferred to a 96-well microplate and assayed for luci-
ferase activity using a LUMIstar Galaxy luminometer
(BMG Labtechnologies). Luciferase activity was reported
as relative luciferase units (RLU). The response of the cells
to BMPs remained constant for at least 10 passages. When
cells reached the 10th passage, they were replaced with
cells recovered from a frozen early passage stock.
For co-culture experiments, test cells were added at the
densities indicated (see figure legends) in 96-well plates
and allowed to attach overnight. 4 × 103 C2C12BRA cells/
well were seeded on top and allowed to attach. Wells were
washed once with PBS and incubated with 100 μl of
DMEM supplemented with 10% FBS. After 24 h, luciferase
activity in cell extracts was measured. All results are
expressed as relative luciferase unit (RLU), which is the
value of the raw luciferase activity minus the background,
in order to eliminate variations in calculations of fold
induction due to differences in the background (no BMP)
values between experiments. All assays were performed in
triplicate and repeated at least two times with similar
results.
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